Siltuximab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Siltuximab: From Castleman Disease to Extracutaneous Mastocytoma
One-Sentence Summary
Siltuximab is an anti-interleukin-6 (IL-6) antibody, originally used for Castleman disease (a rare lymphoproliferative disorder). The TxGNN model predicts it may be effective for extracutaneous mastocytoma, but no clinical trials and no publications currently support this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Castleman disease, Kimura disease (from the TxGNN knowledge graph; the Singapore registration records contain no indication text) |
| Predicted New Indication | Extracutaneous mastocytoma |
| TxGNN Prediction Score | 99.64% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled records. Siltuximab is a chimeric monoclonal antibody that targets IL-6. Its efficacy in Castleman disease, a condition driven by dysregulated IL-6 production, has been established. Mechanistically, it could be applicable to other conditions in which IL-6 signaling plays a role.
For extracutaneous mastocytoma, the link is weak. IL-6 signaling has been implicated in mast cell biology, but no clinical or literature support was found for siltuximab in this indication. The prediction should be regarded as a hypothesis generated by the model, not as an evidence-based lead.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14762P | SYLVANT powder for concentrate for solution for infusion 100 mg/vial | Injection, lyophilized powder for solution | Not specified in the registration record |
| SIN14763P | SYLVANT powder for concentrate for solution for infusion 400 mg/vial | Injection, lyophilized powder for solution | Not specified in the registration record |
Both registrations are valid single-ingredient products from Cilag AG.
Safety Considerations
- Drug Interactions: The compiled interaction data lists 100 interacting drugs, of which the 20 reviewed include:
- Major: deferiprone
- Moderate: warfarin, apixaban, rivaroxaban, dicoumarol, simvastatin, tacrolimus, theophylline, aminophylline, oxtriphylline, roflumilast, lidocaine, fentanyl, hydrocodone, nifedipine, tetanus toxoid vaccine
- Minor: zinc salts (sulfate, acetate, gluconate, chloride)
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high (99.64%), but there are no clinical trials or publications for siltuximab in extracutaneous mastocytoma, and the mechanistic link is only a general suggestion of IL-6 involvement. The evidence level is L5.
Among the other predictions generated for this drug, TAFRO syndrome has much stronger support (L4). It has a plausible IL-6-related mechanism, case reports of siltuximab use, and reviews and guidance publications. It would be a better candidate to prioritise for further evaluation.
To proceed, the following is needed:
- Evidence that IL-6 contributes to the disease biology of extracutaneous mastocytoma (preclinical or mechanistic studies)
- Any case reports, observational data or registered trials of siltuximab in this indication
- Mechanism of action data from DrugBank
- HSA package insert warnings and contraindications, to complete the safety screening
- Similarity analysis between the original and predicted indications, and a route-of-administration compatibility check
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.